Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.
Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Yamamoto N, et al. Among authors: chiba y. J Clin Oncol. 2010 Aug 10;28(23):3739-45. doi: 10.1200/JCO.2009.24.5050. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625120 Clinical Trial.
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K. Kidera Y, et al. Among authors: chiba y. Int J Clin Oncol. 2011 Jun;16(3):244-9. doi: 10.1007/s10147-010-0170-6. Epub 2011 Jan 18. Int J Clin Oncol. 2011. PMID: 21243395
Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis.
Imano M, Yasuda A, Itoh T, Satou T, Peng YF, Kato H, Shinkai M, Tsubaki M, Chiba Y, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Furukawa H, Shiozaki H. Imano M, et al. Among authors: chiba y. J Gastrointest Surg. 2012 Dec;16(12):2190-6. doi: 10.1007/s11605-012-2059-3. Epub 2012 Oct 26. J Gastrointest Surg. 2012. PMID: 23099736 Clinical Trial.
Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K. Kidera Y, et al. Among authors: chiba y. PLoS One. 2014 Jul 14;9(7):e101902. doi: 10.1371/journal.pone.0101902. eCollection 2014. PLoS One. 2014. PMID: 25020203 Free PMC article.
A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer.
Peng YF, Imano M, Itoh T, Satoh T, Chiba Y, Imamoto H, Tsubaki M, Nishida S, Yasuda T, Furukawa H. Peng YF, et al. Among authors: chiba y. J Surg Oncol. 2015 Jun;111(8):1041-6. doi: 10.1002/jso.23928. Epub 2015 Jun 7. J Surg Oncol. 2015. PMID: 26060133 Clinical Trial.
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J. Nonagase Y, et al. Among authors: chiba y. Oncotarget. 2016 Dec 20;7(51):84860-84871. doi: 10.18632/oncotarget.12743. Oncotarget. 2016. PMID: 27768588 Free PMC article.
1,630 results